SARASOTA, Florida, Aug. 14, 2015 /PRNewswire/ -- Rock Creek
Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug
development company which has focused on the application of its
lead compound to chronic inflammatory conditions, announced that
the Company will be featured as a presenting company at the 17th
Annual Rodman & Renshaw Global Investment Conference, sponsored
by H.C. Wainwright & Co., LLC.
The conference is being held September 8-10,
2015, at The St. Regis Hotel in New York City.
Logo - http://photos.prnewswire.com/prnh/20150617/223737LOGO
Dr. Michael J. Mullan, CEO of
Rock Creek Pharmaceuticals, Inc. will provide an update on the
Company during the live presentation and will be available to
participate in one-on-one meetings with investors who are
registered to attend the conference.
Event:
|
17th Annual Rodman
& Renshaw Global Investment Conference
|
Date:
|
September 10,
2015
|
Time:
|
01:45 to 02:10
PM
|
Location:
|
Louis XVI B (2nd
floor); The St. Regis Hotel
|
The Rock Creek Pharmaceuticals presentation will also be
available via a live webcast. To access webcast, please click on
the following link: http://wsw.com/webcast/rrshq25/rcpi. The
webcast replay will remain available for 90 days following the live
presentation.
If you are an institutional investor, and would like to attend
the Rock Creek Pharmaceutical presentation, please click on the
following link www.rodm.com to register for the Rodman &
Renshaw conference. Once your registration is confirmed, you will
be prompted to log into the conference website to request a
one-on-one meeting with the management of Rock Creek
Pharmaceuticals, inc.
About Anatabine Citrate:
Rock Creek Pharmaceuticals' compound is a small molecule,
cholinergic agonist which exhibits anti-inflammatory
pharmacological characteristics, distinct from other
anti-inflammatory drugs available such as biologics, steroids and
non-steroidal anti-inflammatories. The Company has sponsored
extensive pre-clinical (in vitro and in vivo) studies resulting in
peer reviewed and published scientific journal articles, covering
models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune
Thyroiditis. All these studies demonstrated the anti-inflammatory
effects of the Company's compound. In addition, the Company's
compilation of human exposure, safety and tolerability data,
derived primarily from human clinical studies and post-marketing
data collection of the previously marketed nutraceutical product,
has provided important insights for clinical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. a is clinical stage drug
development company focused on the discovery, development and
commercialization of new drugs, formulations and compounds that
provide therapies for chronic and acute inflammatory diseases.
For more information, visit:
http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, failure to obtain sufficient capital resources to fund
our development program and operations, results of clinical trials
and/or other studies, the challenges inherent in new product
development initiatives, including the continued development and
approval of anti-inflammatory drug candidates, the effect of any
competitive products, our ability to license and protect our
intellectual property, our significant payables, our ability to
raise additional capital in the future that is necessary to
maintain our business, changes in government policy and/or
regulation, potential litigation by or against us, any governmental
review of our products or practices, pending litigation matters, as
well as other risks discussed from time to time in our filings with
the Securities and Exchange Commission, including, without
limitation, our annual report on Form 10-K for the fiscal year
ended December 31, 2014 filed on
March 12, 2015. We undertake no duty
to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time.
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy & Development
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: 941-251-0488
tjenkins@rockcreekpharmaceuticals.com